Usefulness of whole body positron emission tomography (PET) with 18F-fluoro-2-deoxyglucose (FDG) to detect recurrent ovarian cancer based on asymptomatically elevated serum levels of tumor marker (CA-125 antigen)

Neoplasma

Volumn 49, Issue 5, 2002, Pages 329-333

  Chang, W C ^a   Hung, Y C ^a   Kao, C H ^a   Yen, R F ^b   Shen, Y Y ^c   Lin, C C ^a  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

Author keywords

18F fluoro 2 deoxyglucose (FDG); Ovarian cancer; Positron emission tomography (PET); Tumor marker (CA 125)

Indexed keywords

CA 125 ANTIGEN; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; RADIODIAGNOSIS; RECURRENT CANCER;

EID: 0036448462     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Bast RC Jr, Klug TL, ST John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR Jr, Knapp RC. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309: 883-887.
2. Berek JS, Knapp RC, Malkasian GD, Lavin PT, Whitney C, Niloff JM, Bast RC Jr. CA 125 serum levels correlated with second-look operations among ovarian cancer patients. Obstet Gynecol 1986; 67: 685-689.
3. Chambers SK, Chambers JT, Kohorn EI, Lawrence R, Schwartz PE. Evaluation of the role of second-look surgery in ovarian cancer. Obstet Gynecol 1988; 72: 404-408.
4. Einhorn N, Nilsson B, Sjovall K. Factors influencing survival in carcinoma of the ovary. Study from a well-defined Swedish population. Cancer 1985; 55: 2019-2025.
5. ELSA-CA 125 II In vitro test insert. CIS bio international.
6. Gambhir SS, Czernin J, Schwimmer J, Silverman DHS, Coleman RE, Phelps ME. A tabulated summary of the FDG-PET literature. J Nucl Med 2001; 42: 1S-93S.
7. Hubner KF, McDonald TW, Niethammer JG, Smith GT, Gould HR, Buonocore E. Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[18F]deoxyglucose (2-[18F]FDG). Gynecol Oncol 1993; 51: 197-204.
8. Karlan BY, Hawkins R, Hoh C, Lee M, Tse N, Cane P, Glaspy J. Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma. Gynecol Oncol 1993; 51: 175-181.
9. Kubik Huch RA, Dorffler W, von Schulthess GK, Marincek B, Kochli OR, Seifert B, Haller U, Steinert HC. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol 2000; 10:761-767.
10. Leisure GP, Vesselle HJ, Faulhaber PF, O'Donnell JK, ADler LP, Miraldi F. Technical improvements in fluorine-18-FDG PET imaging of the abdomen and pelvis. J Nucl Med Technol 1997; 25: 115-119.
11. Low RN, Saleh F, Song SY, Shiftan TA, Barone RM, Lacey CG, Goldfarb PM. Treated ovarian cancer: Comparison of MR imaging with serum CA-125 level and physical examination - A longitudinal study. Radiology 1999; 211: 519-528.
12. Megibow AJ, Bosniak MA, Ho AG, Beller U, Hulnick DH, Beckman EM. Accuracy of CT in detection of persistent or recurrent ovarian carcinoma: Correlation with second-look laparotomy. Radiology 1988; 166:341-345.
13. Meier W, Baumgartner L, Stieber P, Hasholzner U, Fateh-Moghadam A. CA 125 based diagnosis and therapy in recurrent ovarian cancer. Anticancer Res 1997; 17: 3019-3020.
14. Nakamoto Y, Saga T, Ishimori T, Mamede M, Togashi K, Higuchi T, Mandai M, Fujii S, Sakahara H, Konishi J. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer. AJR Am J Roentgenol 2001; 176: 1449-1454.
15. Niloff JM, Knapp RC, Lavin PT, Malkasian GD, Berek JS, Mortel R, Whitney C, Zurawski VR Jr, Bast RC Jr. The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer. Am J Obstet Gynecol 1986; 155: 56-60.
16. Pecking AP, Mechelany Corone C, Pichon MF. 1959-1999: From serum markers to 18-FDG in oncology. The experience of the Rene-Huguenin Center. Pathol Biol (Paris) 2000;48:819-824.
17. Prayer L, Kainz C, Kramer J, Stiglbauer R, Schurawitzki H, Baldt M, Schima W, Poelzleitner D, Reinthaller A, Koelbl H. CT and MR accuracy in the detection of tumor recurrence in patients treated for ovarian cancer. J Comput Assist Tomogr 1993; 17: 626-632.
18. Romer W, Avril N, Dose J, Ziegler S, Kuhn W, Herz M, Janicke F, Schwaiger M. Metabolic characterization of ovarian tumors with positron-emission tomography and F-18 fluorodeoxyglucose. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1997; 166: 62-68.
19. Rose PG, Faulhaber P, Miraldi F, Abdul Karim FW. Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: Correlation with second-look laparotomy. Gynecol Oncol 2001; 82: 17-21.
20. Rose PG. Surgery for recurrent ovarian cancer. Semin Oncol 2000; 27: 17-23
21. Shepherd JH. Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol 1989; 96: 889-892.
22. Shields AF, Graham MM, Spence AM. The role of PET imaging in clinical oncology: A current status report. In: Freeman LM, editor. Nuclear Medicine Annual. New York: Raven Press, 1995: 129-168.
23. Trampal C, Maldonado A, Sancho Cuesta F, Morales S, Senor de Uria C, Panades G, Ortega F. Role of the positron emission tomography (PET) in suspected tumor recurrence when there is increased serum tumor markers. Rev Esp Med Nucl 2000; 19: 279-287.
24. Zimny M, Schroder W, Wolters S, Cremerius U, Rath W, Bull U. 18F-fluorodeoxyglucose PET in ovarian carcinoma: Methodology and preliminary results. Nuklearmedizin 1977; 36: 228-233.